TAK-715
TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model[1][2].
Product Specifications
CAS Number
303162-79-0
UNSPSC
12352005
Hazard Statement
H302, H319
Target
Casein Kinase; p38 MAPK; Wnt
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; MAPK/ERK Pathway; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/TAK-715.html
Purity
99.76
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=CC=C1)NC2=NC=CC(C3=C(N=C(S3)CC)C4=CC=CC(C)=C4)=C2
Molecular Formula
C24H21N3OS
Molecular Weight
399.51
Precautions
H302, H319
References & Citations
[1]Saito A, Yamamoto M. Acute oral toxicity of capsaicin in mice and rats[J]. The Journal of toxicological sciences, 1996, 21 (3) : 195-200.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CK1; p38α; p38β; p38γ; p38δ
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
C9orf95 (NMRK1) (N-term) Rabbit Polyclonal Antibody
Carbonic Anhydrase VIII (CPTC-CA8-2), CF640R conjugate, 0.1mg/mL
